How PARN and Telomerase Cooperate to Control Aging and Cancer Risk
A new review reveals how the deadenylase PARN governs telomerase RNA maturation, linking RNA decay to telomere length, aging, and disease.
Summary
PARN is an enzyme best known for trimming poly(A) tails from messenger RNAs, but it also plays a critical role in stabilizing the RNA component of telomerase (TERC). When PARN is deficient, a competing enzyme called PAPD5 over-polyadenylates TERC, marking it for destruction and shortening telomeres. Short telomeres trigger p53 activation and cell senescence, driving telomere biology disorders (TBDs) like dyskeratosis congenita and bone marrow failure. Paradoxically, excess PARN or telomerase reactivation can enable unchecked cell division, fueling cancer. This review synthesizes current molecular evidence connecting PARN, telomerase, and p53 signaling into a unified framework with direct implications for rare genetic diseases, aging, and cancer therapeutics.
Detailed Summary
Telomere maintenance and RNA stability are two processes that have long been studied in separate silos, but mounting evidence reveals they are tightly coupled through the enzyme poly(A)-specific ribonuclease, or PARN. This review from Nitte University Centre for Science Education and Research (India), published in WIREs RNA (2026), synthesizes over three decades of research to map the molecular interplay between PARN and telomerase, explain how disruption of this axis drives human disease, and evaluate emerging therapeutic strategies targeting these pathways.
PARN is a 3′–5′ exoribonuclease with three key domains — an RNA recognition motif (RRM), a nuclease domain, and an R3H domain — making it the only known deadenylase that can simultaneously engage both the 5′ cap and the 3′ poly(A) tail of an RNA molecule. Its primary textbook role is initiating deadenylation-dependent mRNA decay by shortening poly(A) tails on transcripts containing AU-rich elements (AREs). Notable ARE-containing substrates include TP53, c-MYC, c-FOS, and TNF-α, placing PARN at the center of stress response and oncogenic signaling. During DNA damage, the CBP80-mediated inhibition of PARN is relieved through BARD1/BRCA1 and Cstf1 complexes, allowing p53 to directly engage PARN and promote decay of specific transcripts — revealing a bidirectional regulatory relationship between PARN and p53.
The most consequential non-canonical function of PARN is the processing and maturation of TERC, the RNA template component of telomerase. TERC is transcribed as a precursor that receives a 3′ oligoadenylate tail from PAPD5 (also known as TRF4-2), which normally serves as a processing signal. PARN trims these adenosine residues, protecting TERC from exosome-mediated degradation and enabling its assembly into the functional telomerase holoenzyme with TERT and Dyskerin. When PARN is mutated or absent, PAPD5-mediated polyadenylation is left unchecked, TERC is degraded, telomerase activity drops, and telomeres shorten progressively across cell divisions. Importantly, pharmacological inhibition of PAPD5 in PARN-deficient model systems has been shown to partially rescue TERC levels and telomerase activity, identifying the PAPD5/PARN axis as a tractable therapeutic target.
Pathogenic variants in PARN have been identified in patients with several telomere biology disorders (TBDs), including dyskeratosis congenita, idiopathic pulmonary fibrosis, aplastic anemia, and Hoyeraal-Hreidarsson syndrome. These disorders share a hallmark of critically short telomeres in hematopoietic and epithelial stem cell compartments, leading to bone marrow failure, pulmonary fibrosis, and high cancer predisposition. The review highlights that PARN also processes H/ACA box small nucleolar RNAs (snoRNAs) and pre-miRNAs, whose dysregulation in PARN-deficient states compounds genomic instability. Critically short telomeres activate persistent p53 signaling, which in turn further suppresses PARN activity — creating a feedforward loop that accelerates cellular aging and dysfunction.
The 'Goldilocks' principle of telomere biology is central to understanding why both too-short and too-long telomeres are pathological. While PARN deficiency drives telomere shortening and premature aging phenotypes, elevated PARN activity combined with telomerase reactivation permits cancer cells to maintain abnormally long telomeres, fueling uncontrolled proliferation. The review discusses therapeutic strategies including PAPD5 inhibitors (e.g., BCH001), androgens such as danazol that modestly upregulate TERT expression, and exploratory TERT gene therapy approaches. The authors also flag the TERRA (telomeric repeat-containing RNA) transcripts as important PARN substrates that modulate telomere chromatin architecture, adding another layer of regulatory complexity. Taken together, this review presents the PARN–telomerase axis as a central node integrating RNA homeostasis, telomere integrity, p53 signaling, and cancer risk — a framework with significant implications for both rare disease diagnosis and broader longevity medicine.
Key Findings
- PARN deficiency leads to PAPD5-driven over-polyadenylation of TERC, targeting it for exosomal degradation and reducing functional telomerase levels — a mechanism confirmed in patient-derived PARN-mutant cell lines.
- Pharmacological inhibition of PAPD5 (e.g., with compound BCH001) in PARN-deficient models partially rescues TERC abundance and telomerase activity, representing a validated therapeutic strategy.
- Pathogenic PARN variants have been identified across multiple telomere biology disorders including dyskeratosis congenita, aplastic anemia, idiopathic pulmonary fibrosis, and Hoyeraal-Hreidarsson syndrome, establishing PARN as a TBD gene.
- p53 directly interacts with the PARN–Cstf1–BARD1 complex during DNA damage response to promote deadenylation, while conversely, persistent p53 activation from short telomeres further suppresses PARN — forming a pathological feedforward loop.
- PARN processes at least three classes of noncoding RNA substrates critical for telomere maintenance: TERC precursors, H/ACA box snoRNAs (including those required for Dyskerin-mediated TERC pseudouridylation), and TERRA transcripts.
- Androgen therapy (danazol) modestly upregulates TERT expression and has shown stabilization of telomere length in early clinical trials for TBD patients, though effects are limited in severe PARN loss-of-function cases.
- The 'Goldilocks' telomere model posits that both PARN deficiency (too-short telomeres → TBDs) and excessive PARN/telomerase activity (too-long telomeres → cancer) represent opposite ends of the same disease spectrum.
Methodology
This is a comprehensive narrative review article, not a primary experimental study, and therefore includes no original patient cohorts, sample sizes, or statistical analyses. The authors systematically synthesized published molecular biology, genetics, and clinical literature on PARN and telomerase, drawing on cell line studies, mouse models, patient-derived variant data, and early-phase clinical trials. No control groups or statistical methods apply; the strength of conclusions rests on the convergence of evidence across multiple independent experimental systems.
Study Limitations
As a review article, this work does not present new experimental data, and causal conclusions depend entirely on the quality and reproducibility of the cited primary literature, which spans diverse model organisms and cell types. The therapeutic strategies discussed (PAPD5 inhibitors, TERT gene therapy) remain largely preclinical or in very early human trials, and clinical efficacy data in TBD patients are limited. The authors declare no conflicts of interest, and the work was produced at a single academic institution without external funding disclosures noted in the available text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: